Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    nct00890162
Show Display Options
Rank Status Study
1 Recruiting A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis
Conditions: Anaphylaxis;   Hypotension;   Bronchospasm;   Angioedema
Interventions: Drug: Epinephrine;   Procedure: Bone Marrow Apsiration;   Drug: Omalizumab (Xolair)

Indicates status has not been verified in more than two years